Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
20.31
+0.22 (1.10%)
Dec 20, 2024, 4:00 PM EST - Market closed
Genmab Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Genmab stock have an average target of 43, with a low estimate of 31 and a high estimate of 50. The average target predicts an increase of 111.72% from the current stock price of 20.31.
Analyst Consensus: Buy
* Price targets were last updated on Nov 8, 2024.
Analyst Ratings
The average analyst rating for Genmab stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 1 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Reiterates $46 → $48 | Buy | Reiterates | $46 → $48 | +136.34% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +146.18% | Oct 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +146.18% | Sep 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +146.18% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +146.18% | Sep 13, 2024 |
Financial Forecast
Revenue This Year
21.47B
from 16.47B
Increased by 30.31%
Revenue Next Year
25.01B
from 21.47B
Increased by 16.49%
EPS This Year
86.24
from 66.02
Increased by 30.63%
EPS Next Year
98.92
from 86.24
Increased by 14.70%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 23.0B | 28.2B | 32.5B | |||
| Avg | 21.5B | 25.0B | 28.8B | |||
| Low | 19.6B | 21.0B | 24.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 39.5% | 31.4% | 30.1% | |||
| Avg | 30.3% | 16.5% | 15.1% | |||
| Low | 18.9% | -2.3% | -3.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 98.10 | 141.03 | 187.12 | |||
| Avg | 86.24 | 98.92 | 124.57 | |||
| Low | 75.14 | 71.58 | 86.54 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 48.6% | 63.5% | 89.2% | |||
| Avg | 30.6% | 14.7% | 25.9% | |||
| Low | 13.8% | -17.0% | -12.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.